Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
SB 239063
Cat. No.:
OB0225LY-0399
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR and HPLC.
Size:
Product Overview
Description:
SB 239063 is a selective inhibitor that primarily targets the p38α MAPK pathway. It is valuable in cell signaling studies.
Synonym:
SB239063; 193551-21-2; Cyclohexanol, 4-(4-(4-fluorophenyl)-5-(2-methoxy-4-pyrimidinyl)-1H-imidazol-1-yl)-, trans-; trans-1-(4-Hydroxycyclohexyl)-4-(4-fluorophenyl)-5-(2-methoxypyridimidin-4-yl)imidazole; 4-[4-(4-Fluorophenyl)-5-(2-methoxypyrimidin-4-yl)imidazol-1-yl]cyclohexanol
CAS No.:
193551-21-2
Compound CID:
5166
Formula:
C20H21FN4O2
Formula Weight:
368.4
Specification
Relative Density:
1.35 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
SB 239063 can be used to study signaling pathways associated with cellular stress response and inflammation.
Library Information
Targets:
Kinases
Receptors:
p38α; p38β
Pathways:
Autophagy; MAPK
Plate Number:
AOCL-6
Plate Location:
b5
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
3.7 mg/mL; 10 mM
ALogP:
3.661
HBA_Count:
4
HBD_Count:
1
Rotatable Bond:
4
